Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Heptameric targeting ligands against EGFR and HER2 with high stability and avidity.

Kim D, Yan Y, Valencia CA, Liu R.

PLoS One. 2012;7(8):e43077. doi: 10.1371/journal.pone.0043077. Epub 2012 Aug 9.

2.

Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.

Wållberg H, Löfdahl PK, Tschapalda K, Uhlén M, Tolmachev V, Nygren PK, Ståhl S.

Protein Expr Purif. 2011 Mar;76(1):127-35. doi: 10.1016/j.pep.2010.10.008. Epub 2010 Oct 26.

PMID:
21029777
3.

Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule.

Friedman M, Lindström S, Ekerljung L, Andersson-Svahn H, Carlsson J, Brismar H, Gedda L, Frejd FY, Ståhl S.

Biotechnol Appl Biochem. 2009 Aug 21;54(2):121-31. doi: 10.1042/BA20090096.

PMID:
19492986
4.

Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule.

Nishimura Y, Mimura W, Mohamed Suffian IF, Amino T, Ishii J, Ogino C, Kondo A.

J Biochem. 2013 Mar;153(3):251-6. doi: 10.1093/jb/mvs140. Epub 2012 Dec 11.

PMID:
23235317
5.

Tribody: robust self-assembled trimeric targeting ligands with high stability and significantly improved target-binding strength.

Kim D, Kim SK, Valencia CA, Liu R.

Biochemistry. 2013 Oct 15;52(41):7283-94. doi: 10.1021/bi400716w. Epub 2013 Oct 3.

7.

In vitro and in vivo assessment of targeting lipid-based nanoparticles to the epidermal growth factor-receptor (EGFR) using a novel Heptameric ZEGFR domain.

Benhabbour SR, Luft JC, Kim D, Jain A, Wadhwa S, Parrott MC, Liu R, DeSimone JM, Mumper RJ.

J Control Release. 2012 Feb 28;158(1):63-71. doi: 10.1016/j.jconrel.2011.10.013. Epub 2011 Oct 20.

8.

Targeting human epidermal growth factor receptor 2 by a cell-penetrating peptide-affibody bioconjugate.

Govindarajan S, Sivakumar J, Garimidi P, Rangaraj N, Kumar JM, Rao NM, Gopal V.

Biomaterials. 2012 Mar;33(8):2570-82. doi: 10.1016/j.biomaterials.2011.12.003. Epub 2011 Dec 20.

PMID:
22192536
9.

Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands.

Jin P, Zhang J, Beryt M, Turin L, Brdlik C, Feng Y, Bai X, Liu J, Jorgensen B, Shepard HM.

Mol Med. 2009 Jan-Feb;15(1-2):11-20. doi: 10.2119/molmed.2008.00103. Epub 2008 Nov 17.

10.

Generation and evaluation of bispecific affibody molecules for simultaneous targeting of EGFR and HER2.

Ekerljung L, Wållberg H, Sohrabian A, Andersson K, Friedman M, Frejd FY, Ståhl S, Gedda L.

Bioconjug Chem. 2012 Sep 19;23(9):1802-11. Epub 2012 Aug 29.

PMID:
22882002
11.

Selection and characterization of HER2/neu-binding affibody ligands.

Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J, Ståhl S.

Protein Eng Des Sel. 2004 May;17(5):455-62. Epub 2004 Jun 18.

12.

Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule.

Vernet E, Konrad A, Lundberg E, Nygren PA, Gräslund T.

J Immunol Methods. 2008 Sep 30;338(1-2):1-6. doi: 10.1016/j.jim.2008.06.005. Epub 2008 Jul 29.

PMID:
18671978
13.

Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor.

Friedman M, Nordberg E, Höidén-Guthenberg I, Brismar H, Adams GP, Nilsson FY, Carlsson J, Ståhl S.

Protein Eng Des Sel. 2007 Apr;20(4):189-99. Epub 2007 Apr 23.

14.

Design of an optimized scaffold for affibody molecules.

Feldwisch J, Tolmachev V, Lendel C, Herne N, Sjöberg A, Larsson B, Rosik D, Lindqvist E, Fant G, Höidén-Guthenberg I, Galli J, Jonasson P, Abrahmsén L.

J Mol Biol. 2010 Apr 30;398(2):232-47. doi: 10.1016/j.jmb.2010.03.002. Epub 2010 Mar 10.

PMID:
20226194
15.

Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.

Orlova A, Jonsson A, Rosik D, Lundqvist H, Lindborg M, Abrahmsen L, Ekblad C, Frejd FY, Tolmachev V.

J Nucl Med. 2013 Jun;54(6):961-8. doi: 10.2967/jnumed.112.110700. Epub 2013 Mar 25.

16.

Are HER1/EGFR interactions with ligand free HER2 related to the effects of HER1-targeted drugs?

Kurbel S.

Med Hypotheses. 2006;67(6):1355-7. Epub 2006 Aug 4.

PMID:
16890381
17.

Epidermal growth factor receptor ligands as new extracellular targets for the metastasis-promoting S100A4 protein.

Klingelhöfer J, Møller HD, Sumer EU, Berg CH, Poulsen M, Kiryushko D, Soroka V, Ambartsumian N, Grigorian M, Lukanidin EM.

FEBS J. 2009 Oct;276(20):5936-48. doi: 10.1111/j.1742-4658.2009.07274.x. Epub 2009 Sep 9.

18.

A SPR strategy for high-throughput ligand screenings based on synthetic peptides mimicking a selected subdomain of the target protein: a proof of concept on HER2 receptor.

Monfregola L, Vitale RM, Amodeo P, De Luca S.

Bioorg Med Chem. 2009 Oct 1;17(19):7015-20. doi: 10.1016/j.bmc.2009.08.004. Epub 2009 Aug 8.

PMID:
19733086
19.

Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition.

Tolmachev V, Tran TA, Rosik D, Sjöberg A, Abrahmsén L, Orlova A.

J Nucl Med. 2012 Jun;53(6):953-60. doi: 10.2967/jnumed.111.101527. Epub 2012 May 14.

20.

Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.

Malmberg J, Perols A, Varasteh Z, Altai M, Braun A, Sandström M, Garske U, Tolmachev V, Orlova A, Karlström AE.

Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):481-92. doi: 10.1007/s00259-011-1992-9. Epub 2011 Nov 30.

PMID:
22322933
Items per page

Supplemental Content

Write to the Help Desk